Akebia Therapeutics (AKBA) EBT (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of EBT data on file, last reported at -$8.9 million in Q1 2026.

• EBT for Q1 2026 came in at -$8.9 million, down 246.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.8 million (up 58.6% YoY), and the FY2025 annual result was -$3.7 million, up 94.64% from the prior year.
• EBT climbed to -$8.9 million in Q1 2026 per AKBA's latest filing, from -$11.2 million in the prior quarter.
• Over five years, EBT peaked at $29.0 million in Q2 2022 and troughed at -$64.6 million in Q1 2022.
• A 5-year average of -$13.6 million and a median of -$11.2 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT surged 134.44% in 2022, then tumbled 3814.01% in 2024.
• A 5-year view of EBT shows it stood at -$6.5 million in 2022, then jumped by 109.44% to $614000.0 in 2023, then plunged by 3814.01% to -$22.8 million in 2024, then surged by 50.73% to -$11.2 million in 2025, then advanced by 20.53% to -$8.9 million in 2026.
• Business Quant data shows AKBA's EBT at -$8.9 million in Q1 2026, -$11.2 million in Q4 2025, and $1.2 million in Q3 2025.